Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-10,084
Closed -$89.9K 753
2024
Q1
$89.9K Sell
10,084
-5,304
-34% -$58.7K ﹤0.01% 717
2023
Q4
$158K Buy
15,388
+4,673
+44% +$43K 0.01% 671
2023
Q3
$71.4K Buy
10,715
+466
+5% +$7.82K ﹤0.01% 635
2023
Q2
$160K Buy
+10,249
New +$180K 0.01% 648
2021
Q2
Sell
-8,688
Closed -$225K 546
2021
Q1
$225K Buy
+8,688
New +$201K 0.02% 461

Other funds holding ETNB

Chicago Partners Investment Group's ETNB Position: Q2 2024 in Review

Chicago Partners Investment Group sold out of 89bio (ETNB) in Q2 2024, closing a stake of 10,084 shares — an estimated $89.9K sold.

Chicago Partners Investment Group first reported a position in ETNB in Q1 2021 and held it in 5 quarters. The position peaked at $225K in Q1 2021. 145 funds tracked by Wall St. Rank hold ETNB as of Q2 2024.

  • Chicago Partners Investment Group reported no remaining 89bio position as of Q2 2024 after selling out during the quarter.
  • Chicago Partners Investment Group sold 10,084 89bio shares in Q2 2024, an estimated $89.9K.
  • Chicago Partners Investment Group first reported a position in 89bio in Q1 2021 and held it in 5 quarters.
  • Chicago Partners Investment Group's 89bio position peaked at $225K in Q1 2021.
  • 145 funds tracked by Wall St. Rank held 89bio as of Q2 2024.

Based on Chicago Partners Investment Group's 13F filing for Q2 2024, filed 31 Jul 2024.